Establishment of peritumoral injections of angiogenesis inhibitor to control asynchronous oral cancer in elderly patients

2017 Fiscal Year Final Research Report

• Project/Area Number: 26462999
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Surgical dentistry
• Research Institution: University of Fukui
• Principal Investigator: Sano Kazuo 福井大学, 学術研究院医学系部門, 教授 (20145270)
• Project Period (FY): 2014-04-01 – 2018-03-31
• Keywords: 口腔扁平上皮癌 / 血管新生阻害剤 / bevacizumab / 局所投与 / 抗腫瘍効果

Outline of Final Research Achievements

Angiogenesis serves a crucial role in tumor growth. Bevacizumab inhibits the　biological activity of VEGF and is clinically administered by intravenous　injection. As intravenous chemotherapy intensifies the side effects in oral　squamous cell carcinoma (OSCC) patients. Generally, local injections of　antitumor agents decrease side effects. However, the antitumor effects of peritumoral bevacizumab injections in OSCC are not fully understood. The present study examined the effects of peritumoral bevacizumab injections in an experimental nude mouse model of OSCC through immunohistochemical staining and apoptosis assays. Compared with controls, peritumoral bevacizumab injections significantly inhibited tumor growth in OSCC xenografts and treatment with bevacizumab significantly reduced microvessel density and increased level of tumor cell apoptosis. These results support the experimental basis for the clinical development of peritumoral bevacizumab injections for the treatment of OSCC.

Free Research Field

口腔外科学